Outcome | Edoxaban 30 mg QD (n = 255) | Enoxaparin 2000 IU BID (n = 248) | Absolute difference % (95 % CI) | ||
---|---|---|---|---|---|
n (%) | 95 % CI | n (%) | 95 % CI | ||
Primary efficacy (any VTE) | 6 (2.4) | 1.1, 5.0 | 17 (6.9) | 4.3, 10.7 | −4.5 (−8.6, −0.9)a,b |
Asymptomatic DVT | |||||
Totalc | 6 (2.4) | 1.1, 5.0 | 17 (6.9) | 4.3, 10.7 | −4.5 (−8.6, −0.9) |
Proximal | 1 (0.4) | 0.1, 2.2 | 2 (0.8) | 0.2, 2.9 | −0.4 (−2.5, 1.5) |
Distal | 6 (2.4) | 1.1, 5.0 | 16 (6.5) | 4.0, 10.2 | −4.1 (−8.1, −0.6) |
Symptomatic DVT | 0 (0.0) | 0.0, 1.5 | 0 (0.0) | 0.0, 1.5 | 0.0 |
Symptomatic PE | 0 (0.0) | 0.0, 1.5 | 0 (0.0) | 0.0, 1.5 | 0.0 |
VTE-related death | 0 (0.0) | 0.0, 1.5 | 0 (0.0) | 0.0, 1.5 | 0.0 |
Symptomatic DVT, proximal DVT, symptomatic PE, or VTE-related death | 1 (0.4) | 0.1, 2.2 | 2 (0.8) | 0.2, 2.9 | −0.4 (−2.5, 1.5) |